
CLAIMS

1. Use of a compound belonging to the pyrazolone class of formula (I)



(I)

wherein:

R1 and R2 are independently selected from H, linear or branched C1-C6 alkyl, aryl optionally substituted with OH, C1-C6 alkoxy, linear or branched C1-C6 alkyl or halogen;

R3 is selected from linear or branched C1-C6 alkyl and OH;

R4 is selected from H, linear or branched C1-C8 alkyl, linear or branched C2-C8 alkenyl, a group $-(CH_2)_{1-4}$-CO-linear or branched C1-C6 alkyl, an amino group mono or disubstituted with linear or branched C1-C6 alkyl or with a group $-(CH_2)_{(1-3)}-SO_3H$ and combinations thereof, a -NHCO-aryl or -NHCO-heteroaryl group, and pharmaceutically acceptable salts thereof,

in the manufacture of a medicament for the prevention and/or treatment of at least one degenerative retinal disease.

2. The use according to claim 1, wherein:

R1 and R2 are independently selected from H, linear or branched C1-C3 alkyl, phenyl optionally substituted with OH;

R3 is selected from linear or branched C1-C3 alkyl and OH;

R4 is selected from H, linear or branched C1-C6 alkyl, linear or branched C2-C6 alkenyl, a group $-(CH_2)_{(2-3)}$-CO-linear or branched C1-C4 alkyl, an amino group mono or disubstituted with linear or branched C1-C3 alkyl, with a group $-(CH_2)_{(1-2)}-SO_3H$ and combinations thereof, a –NHCO-nitrogenated heteroaryl group, and pharmaceutically acceptable salts thereof.

3. The use according to claim 1 or claim 2, wherein said compound is selected from aminophenazone, dipyrone, phenazone, propyphenazone, nifenazone, phenylbutazone,

pyrasanone, oxyphenylbutazone, kebuzone, feprazone, mofebutazone, tribuzone and mixtures thereof.

4. The use according to any one of the claims from 1 to 3, wherein said degenerative retinal disease is selected from macular degeneration, diabetic retinopathy, retinal detachment, central serous chorioretinopathy, hypertensive retinopathy, macular hole, macular pucker, myodesopsia (floaters) and myopic maculopathy, preferably macular degeneration.

5. The use according to any one of the claims from1 to 4, wherein said compound is selected from dipyrone, propyphenazone and mixtures thereof.

6. The use according to any one of the claims from 1 to 5, wherein said compound is dipyrone.

7. The use according to any one of the claims from 1 to 5, wherein said compound is propyphenazone.

8. The use according to any one of the claims from 1 to 7, wherein said macular degeneration is dry senile macular degeneration.

9. The use according to any one of the claims from 1 to 7, wherein said macular degeneration is wet senile macular degeneration.

10. Use of a composition comprising at least one compound belonging to the pyrazolone class according to the claims 1 to 3 and at least one pharmaceutically acceptable excipient, in the manufacture of a medicament for the prevention and/or treatment of at least one degenerative retinal disease, wherein said degenerative retinal disease is preferably selected from macular degeneration, diabetic retinopathy, retinal detachment, central serous chorioretinopathy, hypertensive retinopathy, macular hole, macular pucker, myodesopsia (floaters) and myopic maculopathy.

11. The use according to claim 10, wherein said degenerative retinal disease is macular degeneration.

12. The use according to claim 10 or 11, wherein said macular degeneration is dry senile macular degeneration.

13. The use according to claim 10 or 11, wherein said macular degeneration is wet senile macular degeneration.

14. The use according to any one of the claims from 10 to 13, wherein said compound belonging to the pyrazolone class is selected from dipyrone, propyphenazone and mixtures thereof.

15. The use according to any one of the claims from 10 to 14, wherein said compound belonging to the pyrazolone class is dipyrone.

16. The use according to any one of the claims from 10 to 14, wherein said compound belonging to the pyrazolone class is propyphenazone.

17. The use according to any one of the claims from 10 to 16, wherein said composition is an ophthalmic composition comprising at least one compound belonging to the pyrazolone class, and at least one ophthalmologically acceptable excipient.

18. The use according to claim 17, wherein said ophthalmic composition is a topical ophthalmic composition, preferably an aqueous solution.

19. The use according to claim 18, wherein the compound belonging to the pyrazolone class can be present in concentrations ranging from about 0.0001% to about 5% w/v.

20. The use according to claim 19, wherein the compound belonging to the pyrazolone class can be present in concentrations ranging from about 0.01% to about 1% w/v.

21. The use according to claim 19 or 20, wherein the compound belonging to the pyrazolone class can be present in concentrations ranging from about 0.1% to about 1% w/v of the aqueous composition.

22. Use of a combination of at least one compound belonging to the pyrazolone class and an anti-VEGF drug and/or a corticosteroid drug in the manufacture of a medicament for the prevention and/or treatment of at least one degenerative retinal disease selected from macular degeneration, diabetic retinopathy, retinal detachment, central serous chorioretinopathy, hypertensive retinopathy, macular hole, macular pucker, myodesopsia (floaters) and myopic maculopathy.

23. The use according to claim 22, wherein said degenerative retinal disease is macular degeneration, in particular wet senile macular degeneration and/or dry senile macular degeneration.

24. The use according to claim 23, wherein said anti-VEGF drugs are selected from ranibizumab, bevacizumab, or aflibercept.

25. The use according to claim 23 or 24, wherein said corticosteroid drugs are selected from cortisone, prednisone, prednisolone, methylprednisolone, meprednisone, beclomethasone, triamcinolone, paramethasone, mometasone, budesonide, fluocinonide, halcinonide, flumethasone, flunisolide, fluticasone, betamethasone, dexamethasone, hydrocortisone and fluocortolone.

26. The use according to any one of the claims from 22 to 25, wherein said at least one compound belonging to the pyrazolone class is selected from dipyrone, propyphenazone or mixtures thereof.

27. Kit comprising a topical ophthalmic composition, a container containing it and a dispenser, wherein said topical ophthalmic composition comprises at least one compound belonging to the pyrazolone class according to the claims 1 to 3 and at least one pharmaceutically acceptable excipient.

28. The kit according to claim 27, wherein said topical ophthalmic composition is preferably an aqueous solution.